Simplify Logo

Full-Time

IT Systems Manager

Posted on 7/15/2024

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Hardware
Biotechnology
Healthcare

Compensation Overview

$140k - $170kAnnually

+ Performance Bonus + Equity

Senior, Expert

San Francisco, CA, USA

Category
IT Project Management
IT & Security
Required Skills
Microsoft Azure
Communications
Management
Salesforce
AWS
Data Analysis
Requirements
  • Bachelor’s degree in Information Technology, Computer Science, or a related field
  • Minimum of 8 years of progressively responsible experience in related roles, including at least 3 years of IT Systems management experience in a pharmaceutical, biotechnology, or related environment
  • Experience with Veeva CRM, Veeva Align, Salesforce, Adobe Marketo, PromoMats, and Pharma or Commercial MDM data analytics and data warehousing
  • Strong understanding of pharmaceutical commercial and medical affairs operations
  • Proven ability to lead complex integrated solutions, planning, design, and implementation
  • Demonstrated success in managing multiple concurrent priorities
  • Advanced project management skills; PMP or PRINCE2 certification is a plus
  • Proficiency in data analytics tools and techniques
  • Expertise in change management and ensuring smooth transitions during system upgrades
  • Knowledge of regulatory compliance in the pharmaceutical industry (e.g., FDA, GDPR, HIPAA)
  • Experience with cloud platforms (e.g., AWS, Azure) and understanding of cloud-based solutions
  • Knowledge of cybersecurity best practices and experience implementing security measures
  • Strong vendor management skills, including contract negotiation
  • Exceptional communication and collaboration skills
  • Strategic thinker with the ability to innovate and drive continuous improvement
  • Customer-focused with a strong emphasis on enhancing user experience
  • Strong analytical and problem-solving abilities, focusing on delivering practical and effective solutions
  • Highly motivated, with a demonstrated ability to drive results and continuous improvement
  • Ability to operate effectively in a cross-functional/matrix environment
  • High level of personal integrity, consistent with BridgeBio’s values
Responsibilities
  • Manage IT systems supporting Commercial and Medical Affairs teams, including Veeva CRM, Adobe Marketo, Commercial Data Warehouse, Veeva Align, PromoMats, Events Management Platform, Grant Management, and related integrations
  • Act as the IT subject matter expert and trusted advisor for internal stakeholders, maintaining strong vendor relationships
  • Oversee systems backlog and release management, driving continuous improvements to align with evolving business needs
  • Provide comprehensive systems administration and technical support, addressing incidents and service requests, developing training materials, escalating issues, coordinating with vendors, and conducting periodic compliance reviews
  • Collaborate with Commercial and Medical Affairs teams to understand their processes and requirements, providing technical support and training for effective system utilization
  • Develop and maintain detailed system documentation and user guides
  • Engage with key stakeholders, including senior management, to translate their requirements into actionable IT initiatives
  • Identify process improvements and system enhancements opportunities, implementing strategic changes to optimize efficiency and user satisfaction
  • Ensure data integrity, accuracy, and security within CRM and MDM integrations for HCP, HCO, and affiliation data
  • Identify business needs for dashboards, reporting, and KPIs and work closely with vendors to implement tailored solutions
  • Develop and enforce robust data management and governance policies, ensuring regular data clean-ups and reviews
  • Communicate effectively with senior management and key stakeholders, providing clear updates on project and release deliverables, assessing risks, allocating resources, and managing budgets
  • Coordinate with cross-functional teams, including Sales, Marketing, and Medical Affairs, to ensure project success

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company operates using a decentralized subsidiary model, where each subsidiary concentrates on creating therapies for particular diseases while sharing central resources. This structure enhances efficiency and allows for the simultaneous advancement of multiple drug programs. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Unlike many competitors, BridgeBio emphasizes independent thinking and transparency, enabling rapid, data-driven decision-making. The company's goal is to create significant therapeutic advancements by targeting diseases at their genetic source, ultimately bringing effective treatments to market more quickly.

Company Stage

IPO

Total Funding

$6.8B

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

53%

2 year growth

56%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments, such as the $46.84 million from Norges Bank and $200 million for the oncology spinout, indicate strong financial backing and growth potential.
  • The launch of BridgeBio Oncology Therapeutics with $200 million in funding highlights the company's commitment to advancing cancer treatments, particularly KRAS inhibitors.
  • Equity grants to new employees under the Amended and Restated 2019 Inducement Equity Plan demonstrate BridgeBio's commitment to attracting and retaining top talent.

What critics are saying

  • The competitive landscape in genetic disease therapies and oncology is intense, with numerous companies vying for market share.
  • The decentralized subsidiary model, while efficient, may lead to challenges in maintaining cohesive strategic direction and operational alignment.

What makes BridgeBio unique

  • BridgeBio's decentralized subsidiary model allows for focused and efficient drug development across multiple genetic diseases simultaneously, unlike traditional centralized biopharma companies.
  • The company's emphasis on genetic diseases with well-understood causes enables targeted and potentially more effective therapies, setting it apart from competitors with broader, less focused pipelines.
  • BridgeBio's robust pipeline of over 15 drug programs targeting 20 different genetic diseases showcases its diversified approach, reducing the traditional biopharma process timeline.
INACTIVE